

## Chemotherapy drug regimens as part of the AIM Oncology/Cancer Care Quality Program

Regimen Name	Pathway Pathologies	Pathway Stages	Pathway BioMarkers	Pathway Line of Treatment	Pathologies	Consensus Group(s)
Zytiga (Abiraterone Acetate) and Prednisone (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	FDA; NCCN Category 1
Zytiga (Abiraterone Acetate) (1000 mg); Prednisone and Zoladex (Goserelin) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	FDA; NCCN Category 1
Zytiga (Abiraterone Acetate); Prednisone and Lupron (Leuprolide Acetate) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	FDA; NCCN Category 1
Zytiga (Abiraterone Acetate); Prednisone and Trelstar (Triptorelin Pamoate) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	FDA; NCCN Category 1
Zytiga (Abiraterone Acetate) and Prednisone (Castration Resistant; Metastatic; First Line)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line	Adenocarcinoma	FDA; NCCN Category 1; NCCN Category 2A
Zytiga (Abiraterone) (1000mg) and Prednisone (Metastatic; Second Line or Greater)	Adenocarcinoma	IVB; Recurrent		Second Line +	Adenocarcinoma	FDA; NCCN Category 1; NCCN Category 2A; NCCN Category 2B
Zytiga (Abiraterone Acetate) with Zoladex (Goserelin Acetate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line +	Adenocarcinoma	

Zytiga (Abiraterone Acetate) with Lupron (Leuprolide Acetate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line +	Adenocarcinoma	
Zytiga (Abiraterone Acetate) with Trelstar (Triptorelin Pamoate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line +	Adenocarcinoma	
Arimidex (Anastrozole) (Palliative; Stage IV or Recurrent)	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	NCCN Category 2A; NCI-PDQ

<p>Arimidex (Anastrozole) With Monthly Zoladex (Goserelin)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre- menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 2A</p>
<p>Arimidex (Anastrozole) with Monthly Leuprolide (3.75 mg)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre- menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 2A</p>

Arimidex (Anastrozole) with Monthly Leuprolide (7.5 mg)	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	NCCN Category 2A
Erleada (Apalutamide) (Castration Sensitive; Metastatic/Recurrent First Line or Greater)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	NCCN Category 1
Erleada (Apalutamide) and Zoladex (Goserelin Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	NCCN Category 1
Erleada (Apalutamide) and Lupron (Leuprolide Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	NCCN Category 1
Erleada (Apalutamide) and Trelstar (Triptorelin Pamoate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	NCCN Category 1

Clarithromycin and Amoxicillin (Gastric MALT; H-Pylori Positive; First Line) (W)	MALT - Gastric	IA-E, IB-E, IIA-E, IIB-E		First Line	MALT - Gastric	
Clarithromycin and Metronidazole (Gastric MALT; H-Pylori Positive; First Line)	MALT - Gastric	IA-E, IB-E, IIA-E, IIB-E		First Line	MALT - Gastric	
Xtandi (Enzalutamide) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	FDA; NCCN Category 1
Xtandi (Enzalutamide) (Metastatic; 1st Line)	Adenocarcinoma	IVB; Recurrent	Castration-resistant - Yes	First Line	Adenocarcinoma	ASCO; FDA; NCCN Category 1; NCI-PDQ
Xtandi (Enzalutamide) and Zoladex (Goserelin Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	NCCN Category 1
Xtandi (Enzalutamide) and Lupron (Leuprolide Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	NCCN Category 1
Xtandi (Enzalutamide) and Trelstar (Triptorelin Pamoate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	NCCN Category 1

<p>Aromasin (Exemestane) (Stage IV or Recurrent; Palliative)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive</p>	<p>Second Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 2A; NCI- PDQ</p>
<p>Aromasin (Exemestane) With Monthly Goserelin</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre- menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>Second Line, Third Line, Third Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 2A; NCI- PDQ</p>

<p>Aromasin (Exemestane) With Monthly Leuprolide (3.75 mg)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre- menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>Second Line, Third Line, Third Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 2A; NCI- PDQ</p>
<p>Aromasin (Exemestane) With Monthly Leuprolide (7.5 mg)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre- menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>Second Line, Third Line, Third Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 2A; NCI- PDQ</p>

Faslodex (Fulvestrant) 500 mg	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Estrogen Receptor - Positive	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	NCCN Category 1; NCCN Category 2A
Faslodex (Fulvestrant) (No Prior Endocrine Therapy)	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	FDA; NCCN Category 1



<p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment With Goserelin</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 1; NCCN Category 2A</p>
<p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment with Monthly Lupron (Leuprolide) (3.75 mg)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 1; NCCN Category 2A</p>

<p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment with Monthly Lupron (Leuprolide) (7.5 mg)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 1; NCCN Category 2A</p>
<p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 1; NCCN Category 2A</p>

<p>Faslodex (Fulvestrant) with Monthly Goserelin</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 1; NCCN Category 2A</p>
<p>Faslodex (Fulvestrant) with Monthly Leuprolide (3.75 mg)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 1; NCCN Category 2A</p>

Faslodex (Fulvestrant) with Monthly Leuprolide (7.5 mg)	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	NCCN Category 1; NCCN Category 2A
Zoladex (Goserelin Acetate) (For 1-3 Years) (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCCN Category 1; NCCN Category 2A; NCI-PDQ
Zoladex (Goserelin Acetate) for 1-3 years with Bicalutamide or Flutamide (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCCN Category 1; NCCN Category 2A; NCI-PDQ
Zoladex (Goserelin Acetate) For 4-6 Months (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	Adenocarcinoma	AUA; NCCN Category 2A

Zoladex (Goserelin Acetate) For 4-6 Months With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	Adenocarcinoma	AUA; NCCN Category 2A
Zoladex (Goserelin Acetate) For 6 months (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCI-PDQ
Zoladex (Goserelin Acetate) For 6 months with Bicalutamide or Flutamide (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCI-PDQ
Zoladex (Goserelin Acetate) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A; NCI-PDQ
Zoladex (Goserelin Acetate) Post Prostatectomy with Positive Nodes	Adenocarcinoma	IVA		Adjuvant/ Post-operative	Adenocarcinoma	NCCN Category 1
Zoladex (Goserelin Acetate) and Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - Yes	First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A; NCI-PDQ
Zoladex (Goserelin Acetate) with Bicalutamide or Flutamide (Up to 60 Days for Flare) (Advanced/Metastatic/Recurrent; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent		First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A

Femara (Letrozole) (Stage IV or Recurrent; Palliative)	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	FDA; NCCN Category 2A
Femara (Letrozole) with Monthly Goserelin	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	NCCN Category 2A

<p>Femara (Letrozole) with Monthly Leuprolide (3.75 mg)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 2A</p>
<p>Femara (Letrozole) With Monthly Leuprolide (7.5 mg)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>NCCN Category 2A</p>

Eligard (Leuprolide) 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCCN Category 1; NCCN Category 2A
Lupron (Leuprolide) For 1-3 Years (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCCN Category 1; NCCN Category 2A
Lupron (Leuprolide) For 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCCN Category 1; NCCN Category 2A; NCI-PDQ
Lupron (Leuprolide) For 4-6 Months (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCI-PDQ
Lupron (Leuprolide) For 4-6 Months (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	Adenocarcinoma	NCCN Category 2A
Lupron (Leuprolide) For 4-6 Months with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCI-PDQ
Lupron (Leuprolide) For 4-6 Months With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	Adenocarcinoma	NCCN Category 2A



Lupron (Leuprolide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A; NCI-PDQ
Lupron (Leuprolide Acetate) Post Prostatectomy with Positive Nodes	Adenocarcinoma	IVA		Adjuvant/ Post-operative	Adenocarcinoma	NCCN Category 1
Lupron (Leuprolide) and Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - Yes	First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A
Lupron (Leuprolide Acetate) with Bicalutamide or Flutamide (Up to 60 Days For Flare) (Advanced/Metastatic/Recurrent; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent		First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A
Tamoxifen (Stage IV or Recurrent; 1st Line or Greater)	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Menopausal Status - Pre-menopausal	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	FDA; NCCN Category 2A; NCI-PDQ

Tamoxifen (Recurrent; First Line or Greater)	Adenocarcinoma; Cystadenocarcinoma; Endometroid Carcinoma; Epithelial Cancer; Mucinous Cystadenocarcinoma; Primary Peritoneal; Serous Cystadenocarcinoma	Recurrent	Platinum Resistant/Refractory - Yes	First Line +	Adenocarcinoma; Cystadenocarcinoma; Endometroid Carcinoma; Epithelial Cancer; Mucinous Cystadenocarcinoma; Primary Peritoneal; Serous Cystadenocarcinoma	NCCN Category 2A; NCCN Category 2B; NCI-PDQ
Tamoxifen with Monthly Goserelin (Premenopausal; Stage IV or Recurrent; 1st Line or Greater)	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	IV; Recurrent	Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Premenopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive	First Line +	Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma	FDA; NCCN Category 2A; NCI-PDQ

<p>Tamoxifen with Monthly Leuprolide (7.5 mg) (Stage IV or Recurrent; 1st Line or Greater) (W)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IA; IB; IIA; IIB; IIIA; IIIB; IIIC; IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>FDA; NCCN Category 2A; NCI-PDQ</p>
<p>Tamoxifen with Monthly Lupron (Leuprolide Acetate) (3.75) (Stages I-IV/Recurrent; 1st Line or Greater)</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>IA; IB; IIA; IIB; IIIA; IIIB; IIIC; IV; Recurrent</p>	<p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p>	<p>First Line +</p>	<p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p>	<p>FDA; NCCN Category 2A; NCI-PDQ</p>

Trelstar (Triptorelin) Post Prostatectomy with Positive Nodes	Adenocarcinoma	IVA		Adjuvant/ Post-operative	Adenocarcinoma	NCCN Category 1
Trelstar (Triptorelin Pamoate) (For 1-3 Years) (Stages IIC-IVA; High/Very High/Regional Risk; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCCN Category 1; NCCN Category 2A; NCI-PDQ
Trelstar (Triptorelin Pamoate) For 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk; 1st Line)	Adenocarcinoma	IIC; III; IIIA; IIIB; IIIC; IVA	Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional	First Line	Adenocarcinoma	NCCN Category 1; NCCN Category 2A; NCI-PDQ
Trelstar (Triptorelin Pamoate) (For 4-6 Months) (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	Adenocarcinoma	NCCN Category 2A
Trelstar (Triptorelin Pamoate) (For 4-6 Months) With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)	Adenocarcinoma	IIA; IIB; IIC	Prostate Cancer Recurrence Risk - Unfavorable Intermediate	First Line	Adenocarcinoma	NCCN Category 2A
Trelstar (Triptorelin Pamoate) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - No	First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A; NCI-PDQ
Trelstar (Triptorelin Pamoate) with Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent	Castration-resistant - Yes	First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A

Trelstar (Triptorelin Pamoate) with Bicalutamide or Flutamide (Up to 60 Days For Flare) (Advanced/Metastatic/Recurrent; 1st Line or Greater)	Adenocarcinoma	IVB, Recurrent		First Line +	Adenocarcinoma	ASCO; FDA; NCCN Category 2A
---	----------------	-------------------	--	--------------	----------------	--------------------------------

Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Virginia, Inc. Anthem Blue Cross and Blue Shield, and its affiliate HealthKeepers, Inc., serving all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123, are independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.